Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Amortization of Deferred Charges: 2017-2025

Historic Amortization of Deferred Charges for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $326,000.

  • Cidara Therapeutics' Amortization of Deferred Charges rose 13.59% to $326,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 22.05%. This contributed to the annual value of $1.0 million for FY2024, which is 9.50% down from last year.
  • Cidara Therapeutics' Amortization of Deferred Charges amounted to $326,000 in Q3 2025, which was up 3.82% from $314,000 recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Amortization of Deferred Charges registered a high of $1.3 million during Q3 2022, and its lowest value of -$2.1 million during Q4 2021.
  • In the last 3 years, Cidara Therapeutics' Amortization of Deferred Charges had a median value of $287,000 in 2024 and averaged $286,455.
  • In the last 5 years, Cidara Therapeutics' Amortization of Deferred Charges crashed by 378.03% in 2021 and then surged by 7,700.00% in 2022.
  • Cidara Therapeutics' Amortization of Deferred Charges (Quarterly) stood at -$2.1 million in 2021, then skyrocketed by 62.12% to -$791,000 in 2022, then skyrocketed by 133.25% to $263,000 in 2023, then grew by 12.17% to $295,000 in 2024, then rose by 13.59% to $326,000 in 2025.
  • Its Amortization of Deferred Charges was $326,000 in Q3 2025, compared to $314,000 in Q2 2025 and $305,000 in Q1 2025.